Genenta is a clinical stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors.
Our platform is not tumor type nor target antigen restricted and provides sustained targeted expression of therapeutic payload(s) inside the tumor micro environment.
Genenta’s lead product candidate, Temferon™, precisely targets the delivery of interferon-alpha to the tumor micro-environment, minimizing systemic toxicity while breaking tumor-induced immune tolerance.
Our treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.
News and events
Made Film Festival
preview screening of the original web series *"IDEAS – Italian Dialogues on Excellence, Arts, and Science"*. Produced by MAECI – Ministry of Foreign Affairs and International Cooperation (editorial direction by Giorgio Cappozzo, directed by Marco Capriotti, in collaboration with La Loba Production)
Speaker:Pierluigi Paracchi, CEO Genenta Science
Date: November 16, 2024 at: 10:30 am CET
Where: Bergamo
Supporting Materials
Details
Milan Life Science forum 24 by Assolombarda
Investire sulla salute, crescere come sistema
Speaker:Pierluigi Paracchi, CEO Genenta Science
Date: November 26, 2024 at: 9:30 am CET
Where: in person event Assolombarda Via Pantano9, Milano AUDITORIUM GIORGIO SQUINZI
Supporting Materials
Details
SVIZZERA E ITALIA IN DIALOGO
L’innovazione al servizio della vita
Speaker:Pierluigi Paracchi, CEO Genenta Science
Date: November 28, 2024 at: 4:30 pm CET
Where: in person event Rome Italy Ambasciata di Svizzera in Italia
PIPELINE
With an initial clinical focus
on solid tumors with major unmet needs, Genenta’s platform of
autologous oncology products,
led by Temferon
in Phase 1/2a in glioblastoma,
is advancing through preclinical
and clinical assessment.
SCIENTIFIC BOARD
Our Scientists bring a unique
blend of multi-disciplinary
competence, vast experience
in cell therapy a global vision
and a commensurate
track-record in the
forefront of therapies
and drug development.
Myeloid cell-based delivery of IFN-γ reprograms the leukemia microenvironment and induces anti-tumoral immune responses
Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens
IFNα gene/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment
Genenta’s Approach for Cancer Treatment